%0 Journal Article
%T Safety and Efficacy of Oral Mirodenafil in Mexican with Erectile Dysfunction
%A Juan Gerardo Reyes-Garc¨ªa
%A Noem¨ª Santos-Caballero
%A Francisco Javier Flores-Murrieta
%J International Journal of Clinical Medicine
%P 628-638
%@ 2158-2882
%D 2016
%I Scientific Research Publishing
%R 10.4236/ijcm.2016.79069
%X Erectile dysfunction is treated with 5-phospodiesterase inhibitors as Mirodenafil, which has shown its efficacy and safety in Koreans, however; no information in other populations is available. An open clinical trial study was designed to evaluate the efficacy and safety in real life of a fixed-dose of Mirodenafil in Mexican patients with erectile dysfunction. Forty-seven male patients received a 100 mg tablet of Mirodenafil, during 12 weeks. Primary outcome efficacy measure was the percentage of male patients with successful intercourse. Secondary outcomes measures included patient satisfaction, mood and self-esteem level. Safety assessments included laboratory tests, vital signs, physical examination, 12-lead electrocardiogram recordings, and incidence of adverse events by patients. Oral administration of Mirodenafil improved in an 80% - 90% the number of successful intercourses from 7 to 84 days of treatment. Moreover, patients reported a significant increment in their sexual satisfaction, mood and self-esteem. Mirodenafil treatment did not modify vital signs nor anthropometric parameters during 84 days. Mild headache was the most frequent adverse event (17.0%) and there were no severe adverse events during pharmacological treatment. Data suggest that oral Mirodenafil is safety, well tolerated and effective in the Mexican population with erectile dysfunction.
%K Efficacy
%K Erectile Dysfunction
%K Mexicans
%K Mirodenafil
%K Safety
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=70893